These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8925656)

  • 1. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.
    Charache S; Terrin ML; Moore RD; Dover GJ; McMahon RP; Barton FB; Waclawiw M; Eckert SV
    Control Clin Trials; 1995 Dec; 16(6):432-46. PubMed ID: 8925656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).
    McMahon RP; Waclawiw MA; Geller NL; Barton FB; Terrin ML; Bonds DR
    Control Clin Trials; 1997 Oct; 18(5):420-30. PubMed ID: 9315425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
    N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
    Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB
    Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD; Charache S; Terrin ML; Barton FB; Ballas SK
    Am J Hematol; 2000 May; 64(1):26-31. PubMed ID: 10815784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of hydroxyurea on career and employment of patients with sickle cell anemia.
    Ballas SK; Bauserman RL; McCarthy WF; Waclawiw MA;
    J Natl Med Assoc; 2010 Nov; 102(11):993-9. PubMed ID: 21141286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
    N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; DeCastro L; Bellevue R; Barton BA; Waclawiw MA;
    J Natl Med Assoc; 2009 Oct; 101(10):1046-51. PubMed ID: 19860305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
    Jayabose S; Tugal O; Sandoval C; Patel P; Puder D; Lin T; Visintainer P
    J Pediatr; 1996 Oct; 129(4):559-65. PubMed ID: 8859263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxyurea and sickle cell anemia: effect on quality of life.
    Ballas SK; Barton FB; Waclawiw MA; Swerdlow P; Eckman JR; Pegelow CH; Koshy M; Barton BA; Bonds DR
    Health Qual Life Outcomes; 2006 Aug; 4():59. PubMed ID: 16942629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.